The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer

European Journal of Cancer

Volumn 66, Issue , 2016, Pages 83-90

  Kleppe, Marjolein ^a   van der Aa, Maaike A ^b   Van Gorp, Toon ^a   Slangen, Brigitte F M ^a   Kruitwagen, Roy F P M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Netherlands Comprehensive Cancer Organization   (Netherlands)

Author keywords

Chemotherapy; Early stage EOC; Lymph nodes dissection; Survival

Indexed keywords

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COHORT ANALYSIS; CORRELATION ANALYSIS; EARLY CANCER; ENDOMETRIOID CARCINOMA; FEMALE; GROUPS BY AGE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; ADULT; CLINICAL TRIAL; EPIDEMIOLOGY; HOSPITALIZATION; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; REGISTER; STATISTICS AND NUMERICAL DATA;

ANTINEOPLASTIC AGENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; NETHERLANDS; OVARIAN NEOPLASMS; REGISTRIES;

EID: 84981295784     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.07.015     Document Type: Article

References (28)

1. [1] www.seer.cancer.gov.
2. [2] Benedet, J.L., Bender, H., Jones, H. 3rd, Ngan, H.Y., Pecorelli, S., FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 70 (2000), 209–262.
3. [3] Collinson, F., Qian, W., Fossati, R., Lissoni, A., Williams, C., Parmar, M., et al. Optimal treatment of early-stage ovarian cancer. Ann Oncol 25 (2014), 1165–1171.
4. [4] Prat, J., FIGO Committee on Gynecologic Oncology: staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 124 (2014), 1–5.
5. [5] Di Re, F., Baiochocci, G., Value of lymph node assessment in ovarian cancer: status of the art at the end of the second millennium. Int J Gynecol Cancer 10 (2000), 435–442.
6. [6] Colombo, N., Guthrie, D., Chiari, S., Parmar, M., Qian, W., Swart, A.M., et al. International collaborative ovarian neoplasm trial 1: a randomised trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 95 (2003), 125–132.
7. [7] Trimbos, J.B., Vergote, I., Bolis, G., Vermorken, J.B., Mangioni, C., Madronal, C., et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organization for Research and Treatment of Cancer—adjuvant chemotherapy in ovarian neoplasm trial. J Natl Cancer Inst 95 (2003), 113–124.
8. [8] Trimbos, J.B., Parmar, M., Vergote, I., Guthrie, D., Bolis, G., Colombo, N., et al. International collaborative ovarian neoplasm trial 1 and adjuvant chemotherapy in ovarian neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst 95 (2003), 105–112.
9. [9] Carnino, F., Fuda, G., Ciccone, G., Iskra, L., Guercio, E., Dadone, D., et al. Significance of lymph node sampling in epithelial carcinoma of the ovary. Gynecol Oncol 65 (1997), 467–472.
10. [10] Schouten, L.J., van den Brandt, P.A., Jager, J.J., Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol 22 (1993), 369–376.
11. [11] Schouten, L., Jager, J., Van den Brandt, P., Quality of cancer registry data: a comparison of data provided by clinicians with those of registration personnel. Br J Cancer, 68, 1993, 974.
12. [12] Ederer, F., Axtell, L.M., Cutler, S.J., The relative survival rate: a statistical methodology. Natl Cancer Inst Monogr 6 (1961), 101–121.
13. [13] Tropé, C., Kaern, J., Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol 25 (2007), 2909–2920.
14. [14] Timmers, P.J., Zwinderman, A.H., Coens, C., Vergote, I., Trimbos, J.B., Understanding the problem of inadequately staging early ovarian cancer. Eur J Cancer 46 (2010), 880–884.
15. [15] Kleppe, M., Wang, T., Van Gorp, T., Slangen, B.F.M., Kruse, A.J., Kruitwagen, R.F.P.M., Lymph node metastasis in stage I and II ovarian cancer: a review. Gynecol Oncol 123 (2011), 610–614.
16. [16] Onda, T., Yoshikawa, H., Yasugi, T., Mishima, M., Nakagawa, S., Yamada, M., et al. Patients with ovarian carcinoma upstaged to stage III after systematic lymphadenectomy have similar survival to stage I/II patients and superior survival to other stage III patients. Cancer 83 (1998), 1555–1560.
17. [17] Baek, S.-J., Park, J.-Y., Kim, D.-Y., Kim, J.H., Kim, Y.M., Kim, Y.T., et al. Stage IIIC epithelial ovarian cancer classified solely by lymph node metastasis has a more favorable prognosis than other types of stage IIIC epithelial ovarian cancer. JGO 19 (2008), 223–228.
18. [18] Maggioni, A., Benedetti Panici, P., Dell'Anna, T., Landoni, F., Lissoni, A., Pellegrino, A., et al. Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis. Br J Cancer 18 (2006), 699–704.
19. [19] Cress, R.D., Bauer, K., O'Malley, C.D., Kahn, A.R., Schymura, M.J., Stewart, S.L., et al. Surgical staging of early-stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol 121 (2011), 94–99.
20. [20] Chan, J.K., Munro, E.G., Cheung, M.K., Husain, A., Teng, N.N., Berek, J.S., et al. Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 109 (2007), 12–19.
21. [21] Lawrie, T.A., Winter-Roach, B.A., Heus, P., Kitchener, H.C., Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer. Cochrane Database Syst Rev(12), 2015, 10.1002/14651858.CD004706.pub5 Art. No.: CD004706.
22. [22] Trimbos, B., Timmers, P., Pecorelli, S., Coens, C., Ven, K., van der Burg, M., et al. Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial. J Natl Cancer Inst 102 (2010), 982–987.
23. [23] Vergote, I., De Brabanter, J., Fyles, A., Bertelsen, K., Einhorn, N., Sevelda, P., et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357 (2001), 176–182.
24. [24] Ulanday, K.T., Ward, K.K., Macera, C.A., Ji, M., Plaxe, S.C., Regional variation in surgical assessment of lymph node for staging among women with early-stage epithelial ovarian cancer. Gynecol Oncol 132 (2014), 411–415.
25. [25] Powless, C.A., Bakum-Gamez, J.N., Aletti, G., Cilby, W.A., Random peritoneal biopsies have limited value in staging of apparent early-stage epithelial ovarian cancer after thorough exploration. Gynecol Oncol 115 (2009), 86–89.
26. [26] Lee, J.Y., Kim, H.S., Chung, H.H., Kim, J.W., Park, N.H., Song, Y.S., The role of omentectomy and random peritoneal biopsies as part of comprehensive surgical staging in apparent early-stage epithelial ovarian cancer. Ann Surg Oncol 21 (2014), 2762–2766.
27. [27] McNally, L., Teng, N.N.H., Kapp, D.S., Karam, A., Does omentectomy in epithelial ovarian cancer affect survival? An analysis of the surveillance, epidemiology and end results database. Int J Gynecol Cancer 25 (2015), 607–615.
28. [28] Verleye, L., Ottevanger, P.B., Kristensen, G.B., Ehlen, T., Johnson, N., van der Burg, M.E., et al. Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer 47 (2011), 57–64.